Edex (Alprostadil) Patent Expiration, LOE Window & CMS Spending

Edex (Alprostadil) by Endo Pharmaceuticals: Off-Patent Uncontested (0 AB Generics), 0 AB generics, $2K 2024 CMS Part D & Medicaid spend, and 24 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEndo Pharmaceuticals
FDA Application & PathwayN020649 (NDA)
Exclusivity / Cliff HorizonOff-Patent Uncontested (0 AB Generics)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$2K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$2K
Reported Wholesale Price Change (CA SB 17)24 WAC filings (max 19.1% 2-yr change)